Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Exclusion Criteria

• •Previous systemic anti-tumor treatment of Non-small Cell Lung Cancer, including cytotoxic drug therapy, targeted drug therapy (tyrosine kinase inhibitors or monoclonal antibodies) and experimental treatment, etc
• •Previous local radiotherapy of Non-small Cell Lung Cancer
• •Be allergic to any component of Icotinib tablet (Conmana)
• •Other cancers within five years prior to the treatment of this study. Except for cervical carcinoma, basal cell carcinoma and bladder epithelial neoplasm (including Ta and Tis)
• •Any instable systemic disease, including: active infection, high blood pressure out of control, unstable angina, onset of angina pectoris within the past 3 months, congestive heart failure, myocardial infarction, severe arrhythmia, liver, kidney or metabolic disease
• •Previous interstitial lung disease, drug-induced interstitial disease, radiation pneumonia requiring hormone therapy or any active intersexual lung disease with clinical evidence
• •Idiopathic pulmonary fibrosis detected by CT scan at baseline;
• •Not fully controlled eye inflammation or infections, or any condition that may lead to the above eye diseases
• •Human immunodeficiency virus infection
• •Patients undergoing major surgery or severe trauma within 2 months prior to the first use of the experimental drug
• •Patients with Small Cell Lung Cancer
• •Pregnant or lactating women
• •Neurological or psychiatric disorders history, including epilepsy or dementia
• •Other situations not appropriate to enter the group considering by the investigators